Insmed (INSM): Top QQQ Stock to Buy Now

Insmed Incorporated (NASDAQ:INSM) is one of the 9 Best QQQ Stocks to Buy Now. On April 07, Insmed announced that its Phase 2b CEDAR study evaluating brensocatib in adult patients with moderate to severe hidradenitis suppurativa/HS failed to meet its primary or secondary efficacy endpoints. In both the 10 mg and 40 mg treatment arms, the drug did not show a significant advantage over the placebo in reducing the total count of abscesses and inflammatory nodules. Consequently, Insmed has decided to discontinue the development program for brensocatib in the treatment of HS.

The clinical data at Week 16 showed that patients in the 10 mg and 40 mg brensocatib groups experienced reductions in inflammatory counts of 45.5% and 40.3%, respectively, while the placebo group saw a higher reduction of 57.1%. Despite the lack of efficacy, the safety profile of the drug remained consistent with previous trials. No new safety signals were identified, even at the 40 mg dosage, which represented the highest dose studied by the company to date.

Photo by José Antonio Otegui Auzmendi on Pexels

The CEDAR study involved 214 patients across 72 global sites in a randomized, double-blind format. Insmed Incorporated (NASDAQ:INSM) expressed gratitude to the study participants and investigators and plans to share the full data set at a future medical congress.

Insmed Incorporated (NASDAQ:INSM) is a global biopharmaceutical firm focused on developing and commercializing therapies for patients with rare and serious diseases, with key assets including brensocatib and Treprostinil Palmitil Inhalation Powder.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.